Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02840110 · ClinicalTrials.gov registry record
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
A clinical trial, sponsored by Cogent Biosciences.
- Terminated
- Registry status
- 22
- Enrollment target
NCT02840110 is a clinical trial that was terminated before completion, run by Cogent Biosciences. The registered enrollment target is 22 participants.
The verdict
NCT02840110 was terminated before completion, sponsored by Cogent Biosciences.
- TERMINATED
- Registry status
- 22 participants
- Enrollment target
Study Summary
Subjects treated with an ACTR product may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use, named patient Investigational New Drug application, expanded access program, or equivalent setting. No investigational product or treatment will be administered in this study. These subjects will be followed for safety monitoring on a schedule of decreasing frequency through 15 years post-ACTR treatment, in accordance with US FDA Regulatory guidance pertaining to long-term safety follow-up for study subjects receiving recombinant DNA-containing investigational products.
Interventions
- OTHER ACTR T Cell Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-10 |
| Est. Completion | 2021-02-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02840110
The ClinicalTrials.gov registry entry for NCT02840110 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cogent Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACTR T Cell Product is the first listed.
NCT02840110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02840110 about?
NCT02840110 is a clinical study titled "Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product". Subjects treated with an ACTR product may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use, named patient Investigational New Drug application, expanded access prog...
What is the current status of trial NCT02840110?
This trial is currently terminated. The enrollment target is 22 participants. The study started on 2016-10. Estimated completion is 2021-02-23.
What interventions are being tested in trial NCT02840110?
The interventions under investigation include: ACTR T Cell Product (OTHER).
Who is sponsoring clinical trial NCT02840110?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.